Abstract: The present disclosure relates to antagonists that target Serine/Arginine-Rich Splicing Factor 1 (SRSF1); expression vectors comprising SRSF1 antagonists; and the use of such antagonists in therapy for the treatment of neurodegenerative disorders and cancer and screening methods that identify agents that inhibit the expression or activity of SRSF1.

Abstract: The present disclosure relates to antagonists that target Serine/Arginine-Rich Splicing Factor 1 (SRSF1); expression vectors comprising SRSF1 antagonists; and the use of such antagonists in therapy for the treatment of neurodegenerative disorders and cancer and screening methods that identify agents that inhibit the expression or activity of SRSF1.

Abstract: Methods and compositions for identifying an agent (e.g., a gene product or small molecule compound that modulates neuronal cell death in a Parkinson's disease animal model are provided. In practicing the subject methods, a non-mammalian animal model, such as Drosophila melanogaster, that includes a mutant parkin gene and at least one other mutant gene are evaluated for neuronal cell death. Also provided are kits and systems for practicing the subject methods, as well as methods of use of agents identified in the screening method of the invention.

Abstract: Methods and compositions for identifying an agent (e.g., a gene product or small molecule compound) that modulates a Parkinson's disease phenotype are provided. In practicing the subject methods, a non-mammalian animal model, such as Drosophila melanogaster, that includes a mutant parkin gene and at least one other mutant gene are evaluated for a Parkinson's disease phenotype. Also provided are kits, and systems for practicing the subject methods, as well as methods of use of agents identified in the screening method of the invention.